Topamax for neuropathic pain
Executive Summary
Johnson & Johnson will not seek a Topamax (topiramate) indication in diabetic neuropathic pain following Phase III data that failed to demonstrate a statistically significant effect on primary endpoints. Topamax is also in Phase III trials for prevention of migraine headache, treatment of bipolar mania, obesity and partial onset seizures